Bright Minds Biosciences (DRUG) Cash from Financing Activities (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Cash from Financing Activities data on file, last reported at $166.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 105964.77% year-over-year to $166.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.4 million (up 436.15% YoY) and the FY2025 annual result came in at $62.2 million, up 10364.0% from the prior year.
• Cash from Financing Activities rose to $166.6 million in Q1 2026, from $9.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $166.6 million in Q1 2026 to a low of -$17268.5 in Q3 2024.
• A 5-year average of $14.3 million and a median of $9412.1 in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 1295.66% — and 2025, when it jumped 140297.6%.
• Tracing DRUG's Cash from Financing Activities over 5 years: stood at $1.7 million in 2022, then plunged by 61.17% to $644953.8 in 2023, then surged by 5676.14% to $37.3 million in 2024, then slumped by 74.22% to $9.6 million in 2025, then surged by 1634.98% to $166.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $166.6 million (Q1 2026), $9.6 million (Q4 2025), and $24.2 million (Q3 2025), per Business Quant data.